



Omega Pharma group: turnover grows 13 per cent in Second Quarter


Arseus and OTC France confirm turnaround with double digit growth in Q2

Nazareth, Belgium, 19 July 2007 — The consolidated turnover of the Omega Pharma group amounted to 292 million euro in the second quarter, i.e. 13 per cent above the figure for the comparable period last year. Both Consumer Health (OTC) and Arseus (B2B) demonstrated double digit growth in the second quarter. In the Consumer Health division, the strong performance of Omega Pharma France deserves particular attention. In the Arseus division, Arseus Medical registered a growth in turnover of no less than 20 per cent.

The turnover per reporting segment is as follows:

Non-audited management figures in EUR million	Second Quarter			First Half Year		
	2007	2006	Evolution	2007	2006	Evolution
Omega Pharma Belgium	59.7	55.9	+7%	113.9	109.8	+4%
Omega Pharma France	52.8	43.8	+21%	98.4	87.8	+12%
Omega Pharma Northern Europe	30.6	28.1	+9%	54.1	51.3	+5%
Omega Pharma Southern Europe	39.3	38.0	+3%	84.1	75.3	+12%
Omega Pharma Rest Of World	34.8	24.9	+40%	71.4	46.6	+53%
Consumer Health (OTC)	217.2	190.7	+14%	422.0	370.8	+14%
Fagron Group	26.6	24.3	+9%	50.8	47.4	+7%
Corilus	6.3	6.3	+0%	12.4	12.7	-2%
Arseus Dental	29.0	26.1	+11%	57.8	50.6	+14%
Arseus Medical	12.8	10.7	+20%	24.8	22.2	+12%
Professional Health (Arseus)	74.7	67.4	+11%	145.8	132.9	+10%
Total Omega Pharma	291.9	258.1	+13%	567.8	503.7	+13%

Contribution to the consolidated group turnover in the First Half Year 2007



ARSEUS PROFESSIONAL HEALTH (B2B):

Ready for the IPO later this year — a stepping stone for the buy-and-build strategy

This is the third consecutive quarter of solid turnover growth since the 2006 Arseus restructuring: plus five per cent in the last quarter of 2006, plus nine per cent in the first three months of 2007, and plus 11 per cent (double digit) in the past quarter. The current six month turnover is ten per cent above the figure for the same period last year. This clearly demonstrates that Arseus has effectively reached its turnaround point while at the same time laying down solid foundations for the further deployment of its buy-and-build strategy.

- With an internal growth of nine per cent, **Fagron Group** has demonstrated that it is a well-oiled organization ready for geographic expansion. The activities of Polichimica (Italy) will be included in the consolidation circle as of the end of the third quarter 2007. Fagron is currently analyzing opportunities in a number of other countries for acquiring platforms for further growth.
- **Corilus** is also benefiting from the favourable impact of the renewed business model. While the sales decline was already significantly reduced in the previous quarters, the turnover has now been stabilized in the past three months. The turning point for Corilus is also now within reach. The development of Greenock, the new software package for pharmacies, is perfectly on track for its market introduction in early 2008.
- **Arseus Dental** continues to grow consistently. The organization holds a solid position in its traditional home markets of Belgium and the Netherlands, but is also increasing its market penetration in France and Germany. The growth in turnover during the past quarter was in the low double digits, but a well-filled order book justifies a bolder perspective for the future.
- Following the 2006 restructuring, **Arseus Medical** reached its turning point in the first quarter of 2007, demonstrating a four per cent growth in sales. The 20 per cent increase in turnover during the second quarter 2007 underlines the growth potential from the renewed business model. Numerous new distribution contracts provided their first significant sales contribution in the past quarter.

OMEGA CONSUMER HEALTH (OTC):

Solid sales growth while strategic projects have been implemented

In the last two quarters, the turnover of the Consumer Health organization was each time 14 per cent above the comparable period the previous year. When the turnover of Bittner Pharma and Persee Médica is abstracted from the Half Year figures, the turnover grew seven per cent. This is fully in line with the prognoses communicated for the average internal growth in the period leading to 2011.

Simultaneously, a number of important strategic projects aimed at improving efficiency have been initiated or implemented, including: a pilot project (in Belgium) as part of the profitability improvement programme and the reorganisation of the manufacturing site in Finglas (Ireland), including the outsourcing of a number of manufacturing activities. In addition, the integration of Bittner Pharma and Persee Médica continues as scheduled. The fact that all of these projects were combined with a seven per cent internal sales growth confirms that the organization has been significantly strengthened.

For the period 2007-2011, Omega Pharma is now capable of simultaneously focusing on an annual internal growth in turnover of seven per cent on average, as well as on the improvement of the recurring EBITDA margin to 20 per cent of turnover.

All OTC divisions are on track:

- **Omega Pharma Belgium** achieved a seven per cent increase in turnover for the second quarter. The growth of generic products (Stada) has again accelerated, although this increase remains below the growth percentage of 2006 and prior years.
- For the fourth quarter in a row since the restructuring of the sales teams, **Omega Pharma France** posted an increase in its turnover: plus 21 per cent in the past quarter, corresponding to 12 per cent for the first half year. The internal growth (excluding the turnover of Persee Médica) amounted to ten per cent for the second quarter and seven per cent for the first six months of the year. The French organization has significantly outperformed the market and provided convincing proof of its successful turnaround.
- **Omega Pharma Northern Europe** also registered a nice increase in its turnover during the second quarter. Turnover was at a particularly high level in Scandinavia, partly as a result of a powerful campaign for Wartner.
- **Omega Pharma Southern Europe** also performed well in the second quarter. Considering its product range, this organization is optimally evaluated on a half-yearly basis: the 12 per cent increase of turnover confirmed once again the structural strength of the cross-selling strategy as applied by the group.
- **Omega Pharma Rest Of World** recorded the highest percentage growth, thanks in part to the inclusion of Bittner Pharma in the consolidation circle since the beginning of this year. Typical winter products such as Aflubin (against flu) and Bittner Balsam (tonic) reflect a specific seasonality. The turnover of the first half year amounted to over 22 million euro and conforms to expectations.

PROGNOSES⁽¹⁾

Arseus has projected at least a six per cent growth in its turnover in 2007 and even sees the ambitious target of 300 million euro (plus eight per cent YoY) as being within reach.

Thanks to the access that the company now has (as of 2007) to the attractive OTC markets in Central and Eastern Europe, the Consumer Health division projects the 2007 turnover at between 830 and 850 million euro.

Consequently, Omega Pharma reconfirms its prognosis for the 2007 group turnover of between 1,130 and 1,150 million euro (1.13-1.15 billion euro). With the restructuring and refinement of the strategy introduced in 2006, the group also expects a further improvement in all profitability ratios at group level.

For more information, please contact:

Chris.Vanraemdonck@omega-pharma.be — Tel. 0032/9/381.03.31 — Mobile: 0032/499/58.55.31

⁽¹⁾ Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.